Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 89,327,216
  • Shares Outstanding, K 1,103,350
  • Annual Sales, $ 21,222 M
  • Annual Income, $ 2,738 M
  • 36-Month Beta 0.34
  • Price/Sales 4.22
  • Price/Cash Flow 17.13
  • Price/Book 6.37

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.88 +1.35%
on 04/19/17
86.72 -6.64%
on 04/05/17
-3.22 (-3.83%)
since 03/24/17
3-Month
74.00 +9.41%
on 01/31/17
86.72 -6.64%
on 04/05/17
+6.38 (+8.55%)
since 01/26/17
52-Week
64.18 +26.15%
on 11/23/16
86.72 -6.64%
on 04/05/17
+4.69 (+6.15%)
since 04/26/16

Most Recent Stories

More News
Company News for April 26, 2017

Companies in the News are: RAD,GLW,LLY,NFLX

NFLX : 150.17 (-1.31%)
GLW : 28.39 (-0.53%)
RAD : 4.00 (+0.76%)
LLY : 80.96 (-0.30%)
Global Peptide Therapeutics Market to Reach US$46.6 Million by 2024: Increasing Prevalence of Cancer to Create Growth Opportunities, Says TMR

ALBANY, New York, April 26, 2017 /PRNewswire/ --

NVO : 37.36 (+0.76%)
LLY : 80.96 (-0.30%)
Global Peptide Therapeutics Market to Reach US$46.6 Million by 2024: Increasing Prevalence of Cancer to Create Growth Opportunities, Says TMR

According to a new research report by Transparency Market Research (TMR), market players with large revenue base, such as Sanofi, Eli Lilly, Novo Nordisk, and Teva, have been dominating the global peptide...

NVO : 37.36 (+0.76%)
LLY : 80.96 (-0.30%)
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

LLY : 80.96 (-0.30%)
INCY : 123.08 (-1.05%)
SNY : 46.42 (+0.04%)
BIIB : 279.98 (-2.41%)
Key Factors to Look Out for in Celgene's (CELG) Q1 Results

Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.

AGIO : 50.51 (+0.62%)
CELG : 125.20 (-0.25%)
LLY : 80.96 (-0.30%)
NVS : 76.35 (+0.14%)
Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders

As National Autism Awareness Month comes to a close, industry leaders are aiming to keep momentum moving forward, through the development of unique treatments to combat debilitating youth brain diseases...

MYL : 37.44 (+1.60%)
QBIO : 5.1300 (+0.59%)
LLY : 80.96 (-0.30%)
NVS : 76.35 (+0.14%)
SHPG : 175.75 (-0.53%)
Blog Coverage Eli Lilly's Breast Cancer Drug Achieved its Primary Endpoint in Late Stage Trial

Upcoming AWS Coverage on Shire Post-Earnings Results

LLY : 80.96 (-0.30%)
SHPG : 175.75 (-0.53%)
Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly

Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly

LLY : 80.96 (-0.30%)
Lilly Reports First-Quarter 2017 Results

Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2017.

CLCD : 46.53 (+0.06%)
LLY : 80.96 (-0.30%)
3 IPOs to Watch For This Week

The last week of April is scheduled to see eight different companies go public, and Zacks has you covered with three unique IPO offerings to watch out for.

GOOGL : 889.14 (+0.03%)
CELG : 125.20 (-0.25%)
YHOO : 48.26 (-0.29%)
MRK : 62.70 (+0.64%)
LLY : 80.96 (-0.30%)
ORCL : 44.69 (-0.07%)
SHLD : 10.83 (-3.99%)
FB : 146.56 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research...

See More

Support & Resistance

2nd Resistance Point 81.98
1st Resistance Point 81.47
Last Price 80.96
1st Support Level 80.69
2nd Support Level 80.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.